Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron add-on to solifenacin in incontinent overactive bladder after solifenacin run-in
NL-OMON38806Phase 3Not yet recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirabegron and solifenacin in overactive bladder (OAB) and urinary incontinence (UI) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in mean number of incontinence episodes. Planned start Jul 2013; status: not yet recruiting.
02
Drugs
mirabegronsolifenacin
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on NL-OMON38806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38806.